Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies

MLA

Sandra Heskamp, et al. “Bevacizumab Reduces Tumor Targeting of Antiepidermal Growth Factor and Anti-Insulin-like Growth Factor 1 Receptor Antibodies.” International Journal of Cancer, vol. 133, Feb. 2013, pp. 307–14. EBSCOhost, https://doi.org/10.1002/ijc.28046.

APA

Sandra Heskamp, Wim J.G. Oyen, Janneke D.M. Molkenboer-Kuenen, Hanneke W. M. van Laarhoven, Otto C. Boerman, & Winette T. A. van der Graaf. (2013). Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. International Journal of Cancer, 133, 307–314. https://doi.org/10.1002/ijc.28046

Chicago

Sandra Heskamp, Wim J.G. Oyen, Janneke D.M. Molkenboer-Kuenen, Hanneke W. M. van Laarhoven, Otto C. Boerman, and Winette T. A. van der Graaf. 2013. “Bevacizumab Reduces Tumor Targeting of Antiepidermal Growth Factor and Anti-Insulin-like Growth Factor 1 Receptor Antibodies.” International Journal of Cancer 133 (February): 307–14. doi:10.1002/ijc.28046.